Basilea Pharmaceutica

Basilea Pharmaceutica Ltd. is a Switzerland-based biopharmaceutical company that was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. Basilea is engaged in the development of antibacterial and antifungal agents to combat drug resistance.

Additional recommended knowledge

How to quickly check pipettes?

Correct Test Weight Handling Guide: 12 Practical Tips

Safe Weighing Range Ensures Accurate Results

The company is based in Basel, Switzerland. It has subsidiaries in France (Basilea Pharmaceuticals SAS), Germany (Basilea Pharmaceuticals GmbH), Denmark (Basilea Pharmaceuticals A/S), the People's Republic of China (Basilea Pharmaceutica China Ltd), Spain (Basilea Pharmaceuticals Iberia SL), the United Kingdom (Basilea Pharmaceuticals Ltd.), and the United States of America (Basilea Pharmaceuticals Inc.)^[1]. According to stock filings, it had 196 employees as of June 2007^[2].

Basilea currently has no drugs being marketed. It has three investigational drugs in phase III clinical development: ceftobiprole, a cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus (being developed in cooperation with Johnson & Johnson), isavuconazole, a broad-spectrum triazole antifungal drug, and alitretinoin, an oral retinoid for the treatment of Chronic Hand Eczema.^[3]